Danderyd Hospital AB. Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT02434549
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Department of Rehabilitation Medicine, Danderyd Hospital AB. | Olof Skoldenberg

Active Ingredients

Drugs in Phase 2 Trials (3)

denosumab (prolia) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Palsy (Phase 2)

Muscle Spasticity (Phase 2)

Osteolysis (Phase 2)

Paralysis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3